FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聯康生物科技集團有限公司(於開曼群島註冊成立之有限公司) 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00690 | 說明 | 聯康生物科技集團 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 HKD | | 0.01 | HKD | | 5,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000,000 HKD | | 0.01 | HKD | | ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聯康生物科技集團有限公司(於開曼群島註冊成立之有限公司) 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00690 | 說明 | 聯康生物科技集團 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 | HKD | | 0.01 | HKD | | 5,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000,000 | HKD | ...

Core Viewpoint - The recent strategic partnership between 联康生物科技集团 and 科兴生物制药 is aimed at expanding the commercialization of a novel osteoporosis treatment across six countries in the Middle East and Latin America [1] Group 1: Shareholder Activity - On September 23, shareholders of 联康生物科技集团 deposited shares worth HKD 113 million into HSBC Hong Kong, representing 12.33% of the total shareholding [1] Group 2: Strategic Partnership - 联康生物科技集团's wholly-owned subsidiary, 北京博康健基因科技有限公司, has signed a strategic cooperation agreement with 科兴生物制药股份有限公司 [1] - The agreement grants 科兴制药 exclusive commercialization rights for the innovative osteoporosis treatment 博固泰® in six countries: Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico [1]

Core Viewpoint - The recent strategic partnership between Link Health Biotechnology Group and Sinovac Biotech is aimed at expanding the commercialization of a novel osteoporosis treatment in several key markets [1] Group 1: Company Developments - Link Health Biotechnology Group's shareholders deposited shares worth HKD 113 million into HSBC Hong Kong, representing 12.33% of the total shareholding [1] - Link Health's wholly-owned subsidiary, Beijing Bokan Gene Technology Co., Ltd., has signed a strategic cooperation agreement with Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries: Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico [1]

23 September 2025 Uni-Bio Science Group Limited (the "Company") – Notification of Publication of Interim Report 2025 ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.uni-bioscience.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version o ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） （Stock Code 股份代號：0690） NOTIFICATION LETTER 通知信函 Dear Non-registered Holder(s)(Note 1) , 23 September 2025 Uni-Bio Science Group Limited (the "Company") - Notification of Publication of Interim Report 2025 ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.uni-bioscience.com and the website of The Stock Exchange of Hong ...

Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 310,225,000, representing a 13.4% increase from HKD 273,615,000 in the same period of 2024[6] - Gross profit for the same period was HKD 254,084,000, up 10.2% from HKD 230,588,000, with a gross margin of 81.9% compared to 84.3% in 2024[6] - The company achieved a pre-tax profit of HKD 78,649,000, a 10% increase from HKD 71,543,000 in the previous year[7] - The company’s net profit reached approximately HKD 76.0 million, reflecting a year-on-year growth of 12.7%[38] - The total revenue for the group reached approximately HKD 310.2 million, representing a year-on-year growth of 13.4%[46] - Operating profit increased to HKD 79,407,000, compared to HKD 71,808,000 in the previous year, reflecting a growth of 10.9%[80] Research and Development - R&D expenses decreased by 34.7% to HKD 13,634,000 from HKD 20,890,000, accounting for 4.4% of revenue, down from 8.5%[6] - The company is advancing its R&D strategy by focusing on synthetic biology to drive innovation in regenerative medicine, targeting key therapeutic areas such as bone and skin regeneration[17] - Research and development expenses for the six months ended June 30, 2025, amounted to HKD 13,634,000, compared to HKD 23,312,000 for the same period in 2024[97] Market and Product Development - The Chinese pharmaceutical market is projected to grow from RMB 1,551.2 billion in 2018 to RMB 1,733.9 billion in 2024, with an expected reach of RMB 3,318.5 billion by 2035[9] - In the first half of 2025, 43 innovative drugs were approved in China, a 59% increase year-on-year, nearly matching the total of 48 approvals in 2024[9] - The company has six products on the market, including JinYinPeptide® and JinYinShu®[11] - Bogutai® achieved a significant revenue growth of 248.9% year-on-year since its launch in March 2024, reflecting strong market acceptance and clinical application[13] - JinYinKang® received approval from the NMPA on May 21, 2025, marking a key milestone in expanding the company's ophthalmic product portfolio[14] - The launch of GeneQueens™ and JinYinFu® represents a strategic expansion into the medical aesthetics sector, focusing on skin repair and post-operative recovery solutions[15][16] Financial Stability and Liquidity - The cash ratio improved to 1.69 from 0.53, indicating better liquidity management[6] - The company’s debt-to-equity ratio decreased to 45.2% from 58.9%, reflecting improved financial stability[6] - The current ratio increased from 2.58x to 3.40x, reflecting enhanced financial stability[55] - The debt-to-asset ratio improved to 31.1% as of June 30, 2025, down from 37.1% at the end of 2024, indicating better financial stability[66] Strategic Partnerships and Collaborations - The company has established strategic partnerships with API suppliers to secure high-quality raw materials at costs below the industry average, enhancing competitive advantage[14] - The company is collaborating with Chongqing Minji Medical Devices Co., Ltd. to develop recombinant collagen dressings, which received Class II medical device approval in 2024[31] - A collaboration agreement has been signed to jointly develop innovative weight loss drugs, aiming to address multiple key issues related to obesity treatment[29] Product Performance and Sales - The flagship product, Jinyin Peptide®, generated revenue of approximately HKD 107.8 million, an increase of 18.1% year-on-year, attributed to breakthroughs in retail channels and e-commerce expansion[40] - The revenue from the product Boshutai (® Acarbose Tablets) increased significantly by 84.8% to approximately HKD 6.1 million from about HKD 3.3 million, following its inclusion in a centralized procurement program[43] - The revenue from the product Bogutai (® Teriparatide Injection) surged by 248.9% to approximately HKD 65.6 million from about HKD 18.8 million, reflecting strong market promotion efforts[44] Employee and Operational Metrics - Employee costs, including directors' remuneration, increased to HKD 77,665,000 for the six months ended June 30, 2025, from HKD 64,281,000 in the same period of 2024, representing a rise of about 20.9%[98] - The group employed 504 staff members as of June 30, 2025, with a competitive compensation policy to attract and retain top talent[70] Shareholder Information - The largest shareholder, Liang Guolong, holds 1,816,650,464 shares, representing 30.42% of the total issued ordinary shares[121] - Automatic Result Limited holds 1,650,971,464 shares, representing approximately 27.65% of the total shares outstanding[126] - The total number of issued shares as of June 30, 2025, is 5,971,228,147[126] Corporate Governance and Reporting - The company’s interim report, including the condensed consolidated financial statements, has been reviewed by the audit committee[131] - The interim report is published on the Hong Kong Stock Exchange website and the company's official website[132] - No additional interests or short positions were disclosed by directors or key executives as of June 30, 2025[128]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug Bogu Tai® in six countries [1][2] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai® in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai® has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1][2] - Bogu Tai is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The collaboration is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Beijing Bokan Gene Technology Co., Ltd. and Sinovac Biotech Ltd. for the exclusive commercialization of the osteoporosis treatment drug Bogu Tai® in six countries, which presents significant market opportunities [1] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures, addressing unmet medical needs in the market [1] - The target market for this partnership includes over 10 million osteoporosis patients with a market size of nearly $1.5 billion, indicating a substantial opportunity for growth [1] Group 2 - Sinovac Biotech is a leading innovative multinational biopharmaceutical company with operations in multiple countries and regions, which has achieved market access and sales in dozens of global markets [2] - The board of Sinovac Biotech views this collaboration as a key milestone in its global expansion strategy, reinforcing its position in the osteoporosis treatment market and providing long-term value for shareholders [2] - Since its launch in China in March 2024, Bogu Tai® has seen significant success, with revenue growth of 248.9% year-on-year in the first half of 2025, indicating strong market demand and performance [1]